Skip to main content
. Author manuscript; available in PMC: 2022 May 4.
Published in final edited form as: J Drug Target. 2011 Dec;19(10):915–924. doi: 10.3109/1061186X.2011.623701

Figure 4.

Figure 4.

RGDfK-GNR binding to HUVECs in (A) absence and (B) presence of the αv β3 inhibitor echistatin (50 nM) at 4°C for 2 h in binding buffer. Small green-yellow dots indicate presence of GNRs on the cell surface.